New option for management of HIV-I infection in treatment-naive patients: Once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir

HIV/AIDS - Research and Palliative Care

Volumn 4, Issue , 2012, Pages 61-71

  Patel, Nimish ^a   Miller, Christopher D ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

Antiretroviral; Emtricitabine; Human immunodeficiency virus; Rilpivirine; Tenofovir

Indexed keywords

ANTIVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RILPIVIRINE; TENOFOVIR DISOPROXIL;

ABDOMINAL PAIN; ABNORMAL DREAMING; ANTIVIRAL RESISTANCE; BONE DENSITY; CENTRAL NERVOUS SYSTEM DISEASE; COUGHING; CREATININE BLOOD LEVEL; CROSS RESISTANCE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERPIGMENTATION; INSOMNIA; KIDNEY FAILURE; MENTAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; QT INTERVAL; QT PROLONGATION; QUALITY OF LIFE; REVIEW; RHINITIS; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84872965810     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S25149     Document Type: Review

References (72)

1. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229-237.
2. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defc Syndr. 2010;55(1):39-48.
3. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238-246.
4. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance- conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8(5):282-292.
5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
6. Bucher HC, Wolbers M, Porter K. 2010 guidelines for antiretroviral treatment of HIV from the International AIDS Society-USA Panel. JAMA. 2010;304(17):1897; author reply 1897-1898.
7. Mordant C, Schmitt B, Pasquier E, et al. Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. Eur J Med Chem. 2007;42(5):567-579.
8. [No authors listed]. A once-daily combination tablet (Atripla) for HIV. Med Lett Drugs Ther. 2006;48(1244):78-79.
9. [No authors listed]. European Commission approves Atripla. AIDS Patient Care STDS. 2008;22(1):87-88.
10. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumar- ate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defc Syndr. 2008;47(1):74-78.
11. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defc Syndr. 2006;43(5):535-540.
12. [No authors listed]. Atripla approval in Europe. AIDS Patient Care STDS. 2006;20(12):887.
13. Bera E, McCausland K, Nonkwelo R, Mgudlwa B, Chacko S, Majeke B. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital. AIDS. 2010;24(2):283-289.
14. Schouten JT, Krambrink A, Ribaudo HJ, et al. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis. 2010;50(5):787-791.
15. [No authors listed]. FDA notifications. Complera approved. AIDS Alert. 2011;26(11):130-131.
16. Miller V, de Bethune M P, Kober A, et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother. 1998;42(12):3123-3129.
17. Complera® (package insert). Foster City, CA: Gilead Sciences; 2011.
18. Janssen PA, Lewi PJ, Arnold E, et al. In search of a novel anti- HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem. 2005;48(6):1901-1909.
19. Lansdon EB, Brendza KM, Hung M, et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem. 2010;53(10): 4295-4299.
20. Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004;47(10):2550-2560.
21. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses. 2002;18(12):835-838.
22. Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy) propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother. 1998;42(9):2380-2384.
23. Suo Z, Johnson KA. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine. J Biol Chem. 1998;273(42):27250-27258.
24. Ying C, De Clercq E, Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat. 2000;7(1):79-83.
25. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non- nucleoside reverse transcriptase inhibitors. AIDS. 2003;17(1):F1-F5.
26. Richman DD. Antiretroviral activity of emtricitabine, a potent nucleo- side reverse transcriptase inhibitor. Antivir Ther. 2001;6(2):83-88.
27. Hazen R, Lanier ER. Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defc Syndr. 2003;32(3):255-258.
28. Korba BE, Schinazi RF, Cote P, Tennant BC, Gerin JL. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother. 2000;44(6):1757-1760.
29. Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects. AIDS. 2006;20(13):1721-1726.
30. Molina JM, Peytavin G, Perusat S, et al. Pharmacokinetics of emtric- itabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Med. 2004;5(2):99-104.
31. Wang LH, Begley J, St Claire RL III, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses. 2004;20(11):1173-1182.
32. Van Heeswijk RH, Hoetelmans R, Kestens D, et al. The pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteers. Abstract TUPDB01 presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 22-25, 2007, Sydney, Australia.
33. Hawkins T, Veikley W, St Claire RL III, Guyer B, Clark N, Kearney B P. Intracellular pharmacokinetics of tenofovir diphosphate,carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr. 2005;39(4):406-411.
34. Van Heeswijk RH, Hoetelmans R, Aharchi F, et al. The pharmacokinetic (PK) interaction between atorvastatin (AVS) and TMC278, a next- generation non-nucleoside reverse, transcriptase inhibitor (NNRTI). Presented at the 11th European AIDS Conference, October 24-27, 2007, Madrid, Spain.
35. Edurant® (Package insert). Titusville, NJ: Janssen; 2011.
36. Van Heeswijk RH, Hoetelmans R, Kestens D, et al. The pharmacokinetic interaction between ketoconazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor, in healthy HIV-negative subjects. Abstract TUPE0087 presented at the 16th International AIDS Conference, August 13-18, 2006, Toronto, Canada.
37. Kearney B P, Yale K, Shah J, Zhong L, Flaherty JF. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet. 2006;45(11):1115-1124.
38. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115-125.
39. Dejesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodifed anti- retroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defc Syndr. 2009;51(2):163-174.
40. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defc Syndr. 2009;51(5):562-568.
41. Crauwels H, van Heeswijk RPG, Stevens T, et al. Relative bioavail- ability of a concept pediatric formulation of TMC278, an investigational NNRTI. Abstract THPE0158 presented at the XVIIIth International AIDS Conference, July 18-23, 2010, Vienna, Austria.
42. Fatkenheuer G, Duvivier C, Rieger A, et al. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. J Antimicrob Chemother. 2012;67(3):685-690.
43. Rhoads M P, Lanigan J, Smith CJ, Lyall EG. Effect of specifc ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defc Syndr. 2011;57(5):404-412.
44. Wilkin A, Pozniak AL, Morales-Ramirez J, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV Type 1-infected antiretroviral-naive patients: week 192 results from a Phase IIb randomized trial. AIDS Res Hum Retroviruses. October 17, 2011. [Epub ahead of print.]
45. Viread™ (package insert). Foster City, CA: Gilead Sciences; 2012.
46. Blaas S, Schneidewind A, Gluck T, Salzberger B. Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases. AIDS. 2006;20(13):1786-1787.
47. Hynes P, Urbina A, McMeeking A, Barisoni L, Rabenou R. Acute renal failure after initiation of tenofovir disoproxil fumarate. Ren Fail. 2007;29(8):1063-1066.
48. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42(2):283-290.
49. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40(6):1331-1333.
50. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5): 496-505.
51. Irizarry-Alvarado JM, Dwyer J P, Brumble LM, Alvarez S, Mendez JC. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read. 2009;19(3):114-121.
52. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36(8):1070-1073.
53. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002;324(6):342-344.
54. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal func- tion associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40(8):1194-1198.
55. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22(2):99-103.
56. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associ- ated with tenofovir therapy: report of 7 cases. J Acquir Immune Defc Syndr. 2004;35(3):269-273.
57. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir- lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791-1801.
58. Cahn P. Emtricitabine: a new nucleoside analogue for once-daily anti- retroviral therapy. Expert Opin Investig Drugs. 2004;13(1):55-68.
59. Gish RG, Leung N W, Wright TL, et al. Dose range study of pharma- cokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother. 2002;46(6):1734-1740.
60. Emtriva™ (package insert). Foster City, CA: Gilead Sciences; 2007.
61. Nelson M, Schiavone M. Emtricitabine (FTC) for the treatment of HIV infection. Int J Clin Pract. 2004;58(5):504-510.
62. Kuritzkes DR. Drug resistance in HIV-1. Curr Opin Virol. 2011;1(6): 582-589.
63. Das K, Bauman JD, Clark AD Jr, et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic fexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A. 2008;105(5):1466-1471.
64. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a ran- domized trial of nucleoside, nonnucleoside and protease inhibitor- sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109-1118.
65. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combina- tion antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363-371.
66. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phe- notypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defc Syndr. 2012;59(1):39-46.
67. Miller CD, Crain J, Tran B, Patel N. Rilpivirine: a new addition to the anti-HIV-1 armamentarium. Drugs Today (Barc). 2011;47(1):5-15.
68. Hughes CA, Robinson L, Tseng A, MacArthur RD. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profle of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother. 2009;10(15):2445-2466.
69. Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D. Pharmacokinetic parameters of once-daily TMC278 following administration of EFV in healthy volunteers. Abstract 630 presented at the 18th Conference on Retroviruses and Opportunistic Infections. February 27-March 2, 2011, Boston, MA.
70. Mills A, Cohen C, Dejesus E, et al. Switching from efavirenz/emtric- itabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single tablet regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumar- ate (FTC/RPV/TDF) STR in virologically suppressed, HIV-1 infected subjects. Abstract H2-794c presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2011, Chicago, IL.
71. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 17, 2011. Available from: http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Accessed March 8, 2012.
72. Atripla™ (package insert). New York, NY: Bristol-Myers Squibb and Gilead Sciences; 2011.